Carisma Therapeutics (CARM)
OTHER OTC:CARM
Want to see CARM full AI Analyst Report?
CARM Stock Chart & Stats
$0.04
-$0.04(-7.53%)
At close: 4:00 PM EST
$0.04
-$0.04(-7.53%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.56
Previous CloseN/A
Volume72.54K
Average Volume (3M)2.25M
Market Cap
$255.25K
Enterprise Value-$1.76M
Total Cash (Recent Filing)$2.78M
Total Debt (Recent Filing)$762.00K
Price to Earnings (P/E)0.1
Beta5.67
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding41,845,078
10 Day Avg. Volume3,913,183
30 Day Avg. Volume2,245,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.62
Price to Sales (P/S)0.88
P/FCF Ratio-0.29
Enterprise Value/Market Cap-6.88
Enterprise Value/Revenue-0.03
Enterprise Value/Gross Profit-0.03
Enterprise Value/Ebitda-0.13
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe mesothelin targeted autologous CAR monocyte program is expected to show evidence of clinical responses and clean safety, which should de-risk and validate the monocyte platform.
Strategic PartnershipsCarisma will focus on developing off-the-shelf products using its in vivo macrophage engineering platform, including those under the Moderna partnership.
Bears Say
Program DiscontinuationCarisma Therapeutics announced that it would be discontinuing development of its lead program, CT-0525.
Workforce ReductionAs part of the strategic restructuring, Carisma will reduce its workforce by 34%.
Carisma Therapeutics News
CARM FAQ
What was Carisma Therapeutics’s price range in the past 12 months?
Carisma Therapeutics lowest stock price was <$0.01 and its highest was $0.56 in the past 12 months.
What is Carisma Therapeutics’s market cap?
Carisma Therapeutics’s market cap is $255.25K.
When is Carisma Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Carisma Therapeutics’s earnings last quarter?
Currently, no data Available
Is Carisma Therapeutics overvalued?
According to Wall Street analysts Carisma Therapeutics’s price is currently Overvalued.
Does Carisma Therapeutics pay dividends?
Carisma Therapeutics pays a Notavailable dividend of $0.361 which represents an annual dividend yield of N/A. See more information on Carisma Therapeutics dividends here
What is Carisma Therapeutics’s EPS estimate?
Carisma Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Carisma Therapeutics have?
Carisma Therapeutics has 41,845,078 shares outstanding.
What happened to Carisma Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Carisma Therapeutics?
Currently, no hedge funds are holding shares in CARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Carisma Therapeutics
Carisma Therapeutics, Inc. operates as a biopharmaceutical firm dedicated to pioneering chimeric antigen receptor (CAR) macrophage therapies specifically designed to target solid cancerous growths. Its therapeutic approaches are instrumental in modulating both the inherent and acquired functions of the immune system. The company's sophisticated platform draws upon breakthroughs in macrophage science, CAR design, and cell-based treatments to address various human ailments. Notably, Carisma Therapeutics maintains a key strategic alliance with Moderna Inc. Incorporated in 2016 and headquartered in Philadelphia, Pennsylvania, the organization was initially established as CARMA Therapeutics Inc., before rebranding to its current name, Carisma Therapeutics, Inc., in May of 2017.
Technical Analysis
AIM ImmunoTech
―
GT Biopharma
―
Sensei Biotherapeutics
―
Bolt Biotherapeutics
―
CERo Therapeutics Holdings
―
Ownership Overview
― Insiders
0.26% Mutual Funds
3.52% Other Institutional Investors
96.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---